Trusted by 10,000+ Scientists since 2006

Regorafenib (BAY 73-4506)


VEGFR inhibitor

0 Customer Reviews
Catalog No. A10250

Availability:Stock in USAIn stock

Product Name Catalog No. Price Qty
Regorafenib 25mg A10250-25

Regular Price: $50.00

Special Price: $45.00

Regorafenib 100mg A10250-100

Regular Price: $150.00

Special Price: $135.00

Regorafenib (BAY 73-4506) 10mM * 1mL in DMSO A10250-10mM-D

Regular Price: $69.00

Special Price: $62.10

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Quick Overview

Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.

Regorafenib (BAY 73-4506)

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Publications citing Adooq Products
Regorafenib (BAY 73-4506) Citations (2)
  • Takeshi Uenaka, .et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson-s disease, Hum Mol Genet, 2018, Nov 15; 27(22): 3974-3985 PMID: 30137437
  • Yi Xu, .et al. Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2, Free Radic Biol Med, 2016, Jul; 96: 67-77 PMID: 27101738

Chemical Information

Catalog Num A10250
Actions Inhibitor
M. Wt 482.8
Formula C21H15ClF4N4O3
Solubility DMSO
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 755037-03-7
Synonyms N/A

Biological Activity

Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
Target Value
RETIC50: 1.5nM
Raf-1IC50: 2.5nM
VEGFR2IC50: 4.2nM
KitIC50: 7nM
VEGFR1IC50: 13nM
B-Raf(V600E)IC50: 19nM
PDGFRβIC50: 22nM
B-RafIC50: 28nM
VEGFR3IC50: 46nM
FGFR1IC50: 202nM
Tie-2IC50: 311nM


Solubility (25°C) * In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 20.71 mL 103.56 mL 207.13mL
0.5 mM 4.14 mL 20.71 mL 41.43 mL
1 mM 2.07 mL 10.36 mL 20.71 mL
5 mM 0.41 mL 2.07 mL 4.14 mL

*The above data is based on the productmolecular weight 482.8. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Biological Activity

Regorafenib (also known as BAY 73-4506) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. It is currently being studied as a potential treatment option in multiple tumor types.

 Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays. Furthermore, regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β, and fibroblast growth factor receptor 1) and the mutant oncogenic kinases c-KIT, RET, and B-RAF. The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging. Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts. In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 hr after the last dosing and correlated with tumor growth inhibition (TGI). A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg. Regorafenib exhibited potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages observed in breast MDA-MB-231 and renal 786-O carcinoma models. Pharmacodynamic analyses of the breast model revealed strong reduction in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2. These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies


1. Chu E. An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2011 Jul 11. [Epub ahead of print] PubMed PMID: 21752724.

2. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol. 2011 Apr;38 Suppl 1:S10-9. Review.  Erratum in: Semin Oncol. 2011 Jun;38(3):467. PubMed PMID: 21419931.

3. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864. Epub 2011 Apr 22. PubMed PMID: 21170960.

Read More

Ordering online

To place an order online, simply browse to the product you are interested in and click on the 'Add to Cart' button. To complete this process, you will need to confirm the size and quantity of the products that you require.

To complete an order you will need to register using our simple online registration process. We do not share your contact details with any third parties.

When you are ready to check out simply enter your PO number to complete the ordering process. Please ensure that you send us a copy of your PO by fax or email afterwards.  We will then liaise with you or your purchasing department to confirm the order.

Found your products but not ready to order?

Why not use our WishList feature to store lists of products? This convenient feature allows you to manage lists, append notes to products and share lists with co-workers or colleagues.

Ordering offline

You can email or fax us your purchase order and we will place the order for you. You can also phone us to place the order.  Our contact details are:

We require the following information to process your order:
  • The catalog number for each product. 
  • Your email address or fax number. 
  • Your name and telephone number. 
  • Shipping address and billing address.
  • Purchase order numbers.

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

Similar product(s)

Keywords:buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) Supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor | buy 755037-03-7| 755037-03-7 Supplier | purchase 755037-03-7 | 755037-03-7 cost | 755037-03-7 manufacturer | order 755037-03-7 | 755037-03-7 distributor